PhotoCure ASA (FRA:PHS) Valuation Rank


FRA:PHS PhotoCure ASA FRA:PHS
73 GF Score
Price €5.23
GF Value €6.33
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is PhotoCure ASA Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

PhotoCure ASA Valuation Rank Related Terms

FRA:PHS
73GF Score
PhotoCure ASA FRA:PHS
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is PhotoCure ASA (FRA:PHS) Overvalued in 2026?

Based on GuruFocus' analysis, PhotoCure ASA stock appears to be undervalued. The current stock price of €5.23 is trading 17.4% below its estimated GF Value™ of €6.33. GuruFocus considers PhotoCure ASA to be Modestly Undervalued.

Key valuation signals for FRA:PHS:

  • Valuation Rank:
  • GF Value™: €6.33 vs. price of €5.23 (17.4% below fair value)
  • GF Score™: 73/100 with 1 warning sign

No single metric tells the full story. See the FRA:PHS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

PhotoCure ASA Business Description

Address Hoffsveien 4, Oslo, NOR, 0275
PhotoCure ASA is a Norway-based business group associated with the research, development, production, distribution, marketing, and sales of pharmaceutical products and specialty pharmaceutical companies. The technology platform of the company is focused on the field of photodynamic diagnosis and treatment of cancer. The company has two operating segments of the group the Commercial franchise and the Development portfolio. It generates prime revenue from the Commercial franchise segment, which includes Hexvix and Cysview products. Its geographical segments are Nordic countries, Germany, France, Austria, the United Kingdom, BeNeLux, Italy, Other European countries, Canada, and the United States.
73GF Score

Get the complete analysis for FRA:PHS

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.23
Price
€6.33
GF Value